Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt